SHAREHOLDER INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

Group 1 - Rezolute, Inc. shares experienced a significant decline on December 11, 2025, due to disappointing topline results from its Phase 3 sunRIZE clinical trial for the drug candidate ersodetug, which is intended for treating congenital hyperinsulinism [5] - The clinical trial failed to meet both its primary and key secondary endpoints, with the highest dose showing reductions in hypoglycemia events that were not statistically significant compared to placebo [5] - Faruqi & Faruqi, LLP is investigating potential claims against Rezolute, Inc. for investors who suffered significant losses [2][4]